The percentage of BrdU+ cells in the VZ/SVZ (**p = 0.007) and IZ (*p = 0.04) significantly increased in compared to control brains. of BIG1 does not affect commissural axon projection. (A) The CC Nidufexor width relative to the brain height (**p = 0.001) or width (***p = 0.0008) is smaller in brains based on the results in Fig 6Axii-xiii. n = 4 per group. (B) At E17.5, dye tracing showed the commissural axons (yellow arrowheads) in brains can reach contralateral brain hemisphere. Scale bars, 500 m. n = 3 per group. For all bar graphs, Students T-test was used for comparisons between groups. Data are shown as the mean SD. CC, corpus callosum.(TIF) pone.0175888.s004.tif (337K) GUID:?0CCC0F3A-079E-4E2F-BE24-CDBBB8049BA4 S5 Fig: Loss of BIG1 does not affect various parameters of stage III neurons. Various parameters at DIV 2 such as (A) the longest axon length (p = 0.16), (B) the total axon length (p = 0.12), (C) the amount of axon branch (p = 0.36), (D) the longest dendrite length (p = 0.18), (E) the total Rabbit polyclonal to AKR1A1 dendrite length (p = 0.47), (F) the amount of dendrite branch (p = 0.20) and (G) the amount of primary dendrite (p = 0.06) had no significant differences between and control stage III neurons. n 50 neurons per group. (H) DIV 4 neurons can develop long axon (white arrowheads) and dendrites branches (red arrowheads) similar to the control neurons. There was no difference in the percentage of neurons with dendrite Nidufexor branch in and control neurons. n 200 neurons from 4 different embryos per group. Students T-test was used for comparisons between groups. Data are shown as Nidufexor the mean SD.(TIF) pone.0175888.s005.tif (799K) GUID:?7906FDB6-8026-40BD-B829-5FDA03424360 Data Availability StatementAll relevant data are within the paper and its Supporting Information files. Abstract BIG1, an activator protein of the small GTPase, Arf, and encoded by the gene, is one of candidate genes for epileptic encephalopathy. To know the involvement of BIG1 in epileptic encephalopathy, we analyzed BIG1-deficient mice and found that BIG1 regulates neurite outgrowth and brain development and gene, is one of the largest ARF-GEFs found in mammals, and conserved homologues of BIG1 have been found in all eukaryotes studied [8, 11]. This 200 kDa protein was initially identified as a component of a 670 kDa cytosolic macrocomplex purified from the bovine brain [12]. Similar to BIG2 and GBF1, which belongs to the same family, Nidufexor BIG1 contains a 200 amino acids BFA-sensitive Sec7 domain that preferentially activates Class I ARFs, catalyzing the conversion of ARF-GDP to ARF-GTP, thereby initiating the formation of intracellular vesicles [13, 14, 15]. Among the large ARF-GEFs, BIG2 had been shown to be involved in neuronal migration in mammalian brain [16]. Similarly, BIG1 has been shown to regulate neurite development [17]. BIG1 localizes to the Golgi complex, and perturbation of BIG1 with BFA affects the function of the Golgi complex [14, 18]. Meanwhile, in a recent exome-sequencing screening study in human, mutation of studies of BIG1 function in mammalian brain. Here, we elucidate the role of BIG1 in the survival and the connectivity of DL neurons which would help to explain the pathogenicity of epileptic encephalopathy due to mutation of the gene. Materials and methods Ethics statement All animals were bred and housed at the Institute of Animal Experimental Research in Osaka University. All animal experiments conformed to the institutional guidelines and were approved by the Animal Care and Experimentation Committee of Osaka University (Approval No.21-045-0). All animals used in the study were euthanized with an overdosed by isoflurane prior to transcardial perfusion or tissue dissection. All efforts were made to minimize suffering. Antibodies The following primary antibodies were used: anti-BIG1 N-terminal (Santa Cruz, sc-376790), anti-BIG1 C-terminal (Bethyl, A300-998A), anti-Lamin-B (Santa Cruz, sc-6216) anti-Pax6 (Covance, PRB-278P), anti-cleaved-Caspase-3 (Cell Signaling, #9661), anti-Calbindin (Santa Cruz, sc-7691), anti-Prox1 (R&D Systems, AF2727), anti-Ctip2 (Abcam, ab18465, gift from Dr. Makoto Sato, Osaka University), anti-Tbr1 (Chemicon, AB9616; Santa Cruz, sc-15607), anti-Cux1 (Santa Cruz, sc-13024), anti-BrdU (BD Pharmingen, 555627), anti-Map1b (clone 1B6, gift from Dr. Reiko Harada, Takarazuka University of Medical and Health Care) [20], anti-Tau1 (Chemicon, LV1383492), anti-Map2 (Cell Signaling, #4542), anti-Tuj1 (Covance, MMS-435P) and anti-Golgin97 (Gift from Dr. Nobuhiro Nakamura, Kyoto Sangyo University) [21]. The following secondary antibodies were used: HRP-conjugated goat anti-mouse (ICN Pharmaceuticals, 59296), calf anti-rabbit (Rockland, 200C4135) or calf anti-goat (Rockland, 200C1135), Alexa-Fluor-488-labeled or Alexa-Fluor-594-labeled donkey anti-mouse (Invitrogen,.
